Lung cancer is the leading cause of cancer mortality worldwide ([@bib15]). Despite large-scale investments in research and optimisation of treatment strategies, lung cancer is mostly detected at an advanced stage, resulting in a general 5-year survival of 15% ([@bib61]). Prognosis greatly improves if lung cancer is detected at an early stage ([@bib48]).

Lung cancer development evolves in approximately 10 to 30 years before it becomes clinically manifest ([@bib22]). This latency period offers an opportunity to identify individuals at risk. In the past century (in the 1970s), thorax X-ray screening studies have been conducted for the detection of early-stage lung cancer, in which cytological examination of sputum was part of the diagnostic procedure ([@bib43]). Sputum cytology turned out neither to be of additive value in enhancing lung cancer detection nor in reducing lung cancer mortality. The average survival time increased after thorax X-ray screening because of lead time and sampling bias. The outcome of a recent low-dose spiral CT (LDCT) screening study seems promising as it reduces lung cancer mortality ([@bib44]).

In theory, a biomarker sputum test for early detection may be developed for three possible applications: (i) identification of at-risk individuals, who may be screened with LDCT after a positive biomarker test; (ii) after the first LDCT screen shows a solid lesion, a sputum biomarker may be developed as a diagnostic test for malignancy; and (iii) after the first LDCT screen shows a ground glass lesion, we can determine whether the lesion has a high or low chance of becoming malignant. In the setting of patients with symptomatic lung cancer, a sputum test may be useful for diagnostic workup of malignancy and if diagnosed with lung cancer to perform predictive analysis.

Biomarker screening may be categorised into (i) risk markers, which identify individuals at high risk of developing lung cancer, and (ii) diagnostic markers, which uncover invasive lung cancer. The biomarker must meet several conditions, such as being superior to conventional detection methods in terms of sensitivity and specificity, before it is considered suitable for clinical implementation ([Box 1](#box1){ref-type="boxed-text"}). In this review, diagnostic markers are defined as markers recognising (the transition to) invasive lung cancer. At this stage, the disease may be measurable but still asymptomatic. A risk marker is able to identify subjects at risk without measurable disease. In pathobiological terms, this marker may be associated with several conditions, such as measure of exposure to carcinogen and development of carcinoma *in situ* ([@bib55]).

In 2003, a review summarised the status of mutation analysis and initial methylation findings in sputum ([@bib70]). This manuscript provides an overview of developments in sputum analysis for lung cancer diagnosis in the past 10 years. The PubMed terms 'lung cancer\' and 'sputum\' were used. In addition, special attention is paid to DNA hypermethylation.

Sputum cytology
===============

By means of cytology, tumour cells can be identified in sputum through aberrant cell morphology. Status of the diagnostic value of sputum cytology has not changed in the past decennium. In the clinical diagnostic setting, the sensitivity of sputum cytology is ∼60%, which also depends on the number of sputum samples examined ([@bib52]). Although in developed countries the procurement of tumour biopsies/tumour cytology replaced the use of sputum cytology as standard for lung cancer diagnosis ([@bib53]), in lower budget countries sputum cytology is an affordable diagnostic instrument and still clinically implemented ([@bib1]).

Molecular analysis of sputum
============================

DNA mutation analysis
---------------------

For DNA mutation analysis, currently the relevant part of the gene of interest is amplified, usually using polymerase chain reaction (PCR) technology. This is a very sensitive, low-cost, rapid and simple method. Disadvantages are that contamination may be an issue, as well as that the enzyme DNA polymerase has a small error. In about 0.1% of amplicons, an incorrect nucleotide may be incorporated ([@bib14]). If this error happens early in the PCR procedure, it will propagate and may lead to a false-positive signal, thus reducing specificity.

Mutations of tumour-suppressor gene *p53* and oncogene *KRAS* have been identified to have a role in lung carcinogenesis ([@bib19]). In 50% of lung cancer cases, mutations or deletions are present in the *p53* gene ([@bib17]). *KRAS* mutations mostly occur in adenocarcinomas (20--30% in western countries and 10% in eastern countries) ([@bib58]).

Various *KRAS* mutation detection techniques have been investigated on sputum specimens ([Table 1](#tbl1){ref-type="table"}). Peptic nucleic acid--PCR--restriction fragment length polymorphism (PNA--PCR--RFLP) and Point-EXACCT were described as methods of choice ([@bib70]).

[@bib12] confirmed *KRAS* mutation in 79% of the sputum samples from lung cancer patients with a *KRAS* mutation in their tumour tissue (*n*=14). In controls, none tested positive. [@bib29], [@bib31]) conducted studies in Xuan Wei County (China), where lung cancer rates were fivefold higher than the Chinese national average. Mutation detection was optimised by application of cell cytocentrifugation and laser capture microdissection, enabling detection of low fraction mutations, even in morphologically benign bronchial epithelial cells ([@bib29], [@bib31]). With this approach, examination of cytology is still needed for dissecting abnormal or benign epithelial cells for enrichment. In a cancer-free population, mutations in both genes were identified (15 out of 92) ([@bib31]). These mutations occurred in none of the matched buccal epithelial cells, indicating that the latter cells are not suitable as a surrogate marker for lung cancer (risk).

Until recently, most sputum studies have been performed on patients with symptomatic lung cancer. Research conducted before 2003 show that *KRAS* mutations may be detected in sputum at least 1 year before clinical diagnosis of lung cancer ([@bib63]). [@bib3] were the first to investigate sputum from a large LDCT screening cohort (*n*=803) consisting of asymptomatic heavy smokers, assessing frequency of *KRAS* and *p53* mutations, next to DNA promoter hypermethylation of *p16*, *NORE1A* and *RASSF1A* ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). *KRAS* mutation analysis was performed by restriction endonuclease-mediated selective PCR with a reported sensitivity of one mutant per 1000 wild-type genes. No *KRAS* mutation was identified, especially in the 18 subjects who developed lung cancer during the follow-up period. None of these patients had molecular alterations at baseline. In 15 out of 803 (2%) participants, a *p53* mutation was found, of whom one patient was diagnosed with early-stage lung cancer in follow-up without confirmation of the *p53* mutation in the tumour.

These studies suggested that *KRAS* might be more suitable as a diagnostic marker than for risk assessment in precancerous stages. Future studies with further follow-up of participants are needed to elucidate whether molecular alterations of *KRAS* and *p53* are indeed suggestive for lung cancer development.

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (*EGFR*) have been identified in parts of lung adenocarcinomas, and are associated with high response rates to treatment with *EGFR* tyrosine kinase inhibitors ([@bib56]). *Epidermal growth factor receptor* mutation analysis has been performed in some sputum samples as part of larger series of other cytological samples, mostly without detailed information and not compared with the original tumour ([@bib8]; [@bib66]; [@bib68]). In a total of three publications, 3 out of 25 sputum samples were positive in cases with cytologically proven malignant cells.

*EML4-ALK* is a lung cancer fusion oncogene that is estimated to be expressed in 3--6% of lung adenocarcinomas ([@bib67]), showing marked response to treatment with ALK inhibitors ([@bib35]). Recently, [@bib62] reported the development of a multiplex RT--PCR system that was able to detect *EML4-ALK* mutations in 4 out of 35 sputum samples, which were part of a prospective screening cohort of NSCLC patients.

Optimisation of *EGFR* and *EML4-ALK* mutation detection in sputum may, in the future, contribute to minimise the use of invasive bronchoscopy or transthoracic needle biopsies to secure tumour biopsies for mutation testing, a clinical need in monitoring personalised treatment.

DNA hypermethylation
--------------------

Aberrant DNA promoter methylation is a cell control mechanism in lung carcinogenesis ([@bib55]), involving the addition of a methyl group at the carbon 5 position of cytosines at CpG sites in DNA. A widely used approach to distinguish methylated DNA from unmethylated DNA is exposing genomic DNA to bisulphite before PCR. In this process, unmethylated cytosine is converted into uracil, whereas methylated cytosine remains unchanged. The templates are next subjected to methylation-specific PCR (MSP). It has the same (dis)advantages as PCR in mutation analysis ([@bib57]), with an additional disadvantage that bisulphite conversion may be incomplete. In that case, not all unmethylated cytosines are converted to uracil, leading to false-positive results, whereas some controls do not correct for this. In some methods like pyrosequencing ([@bib24]), this incomplete conversion may be detected, but this is not the case with MSP.

To examine the effect of a high number of cycles in MSP, a small interlaboratory study was performed between The Canisius Wilhelmina Hospital in Nijmegen, the Netherlands (CP, ET) and the Fondazione IRCCS Istituto Nazionale Tumouri in Milan, Italy (GZ) with identical set-up (DNA samples, primers and protocols) ([@bib16]). Promoter DNA hypermethylation of *p16* and *β*-retinoic acid receptor (*RAR-B*) ([@bib41]) was investigated using nested MSP analysis with a number of different PCR cycles (50--80 cycles in total). Consistent results between the laboratories were present up to 55 cycles (in total). In experiments with \>55 PCR cycles, a greater number of samples became positive with the loss of reproducibility between and within laboratories. These results point towards false positivity and indicate that caution must be exercised when interpreting data derived from studies in which nested MSP with more than 55 PCR cycles were applied.

Based on this knowledge, we divided literature studies on gene methylation in sputum published up to now into three categories: studies in which \<55 PCR cycles were applied, \>55 PCR cycles or unknown number of PCR cycles, respectively. The latter category consisted of those studies of which the publications did not provide explicitly the number of PCR cycles used.

Hypermethylation frequency in sputum of mostly symptomatic lung cancer patients and controls was investigated for 54 genes ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Not for all genes information could be specified: some genes were described with incomplete data. Furthermore, inclusion and exclusion criteria for both cases and controls differed between the studies. Some studies included only non-small-cell lung cancer, others also examined small-cell lung cancer and unspecified lung cancer cases. The examined populations consisted usually of more male subjects than female subjects (average 75% in cases, 70% in controls, respectively).

From the summary table, it is apparent that only for a limited number of genes published data were available for categories \>55 or ⩽55 PCR cycles, respectively. Concerning *p16* gene, five studies ([@bib7]; [@bib12]; [@bib45]; [@bib11]; [@bib60]) with ⩽55 PCR cycles and nine studies with \>55 PCR cycles ([@bib32]; [@bib46]; [@bib34]; [@bib6]; [@bib23]; [@bib40]; [@bib18]; [@bib36]; [@bib59]) with sensitivity and specificity data were available for bivariate analysis ([@bib51]). Interestingly, mean specificity was shown to be significantly lower in the group of studies with \>55 PCR cycles (74% *vs* 87%, *P*\<0.001), whereas sensitivity was higher, but not significantly different (49% *vs* 33%, *P*=0.13). This literature analysis supports the above-mentioned theoretical notion that a high number of PCR cycles leads to a higher chance of false-positive results. It is not excluded that a diagnostic marker may be looked upon as a risk marker (as defined in [Box 1](#box1){ref-type="boxed-text"}), when \>55 PCR cycles are run with possible induced false positivity. Moreover, when comparing the number of PCR cycles (\>55 or ⩽55) with marker classification (diagnostic *vs* risk), a biomarker is more likely to be classified as a risk marker if \>55 PCR cycles were applied compared with at most 55 PCR cycles (85% *vs* 58%, *P*=0.002).

In 10 studies ([@bib32]; [@bib46]; [@bib10]; [@bib39]; [@bib72]; [@bib12]; [@bib45]; [@bib11]; [@bib4]; [@bib23]) matched tumour and sputum samples were examined. The median frequency of gene hypermethylation was higher in tumour than in sputum samples: 48% (interquartile range 36--64%) *vs* 38% (interquartile range 31--57%), respectively. A meta-analysis on exact data ([@bib32]; [@bib39]; [@bib72]; [@bib45]; [@bib60]; [@bib59]) showed that this observed tendency was not significant (*P*=0.09; [@bib13]). Median concordance of methylation between tumour and matched sputum, calculated from the same studies, is 78% (interquartile range 73--91%), indicating that the use of sputum as non-invasive biological fluid for detection of aberrant methylation is representative of the methylation status of primary tumour tissue.

Still, none of the biomarkers yield 100% sensitivity. The multidimensional character of lung cancer, in which various genes might be involved ([@bib20]), requires a panel of markers that can complement each other in lung cancer detection. Several studies calculated combined sensitivity and specificity for hypermethylated genes ([@bib77]; [@bib5], [@bib6], [@bib4]; [@bib23]), revealing higher performance when compared with the markers individually. These algorithms seem promising, but are scarcely validated in independent study cohorts. Interestingly, one study ([@bib36]) replicated a panel of previously published hypermethylation markers ([@bib4]) in two independent slightly different cohorts: case--control *vs* asymptomatic stage I lung cancer patients. They showed a slightly higher sensitivity and specificity in the second cohort. However, the methylation panels were not exactly similar between the study cohorts. Also, as sputum samples were stored in Saccomanno after collection without further treatment, DNA quality may be reduced, possibly affecting the study data. Therefore, at this point in time, it is difficult to define an unambiguous biomarker signature panel for lung cancer risk based on these results.

Patient selection, sputum collection and procedure methods might explain the differences in rates of methylation between studies investigating the same biomarker.

Research into additional novel markers remains necessary.

Loss of heterozygosity
----------------------

Microsatellite alterations present as loss of heterozygosity (LOH), or as microsatellite instability (MSI). Conceptually, LOH is essentially different from previous markers, because it explores the absence of the allele that is present in the normal situation, whereas the other above-mentioned biomarkers look for the presence of a specific abnormality. Because the fraction of tumour cells in sputum is usually \<1%, the majority of the cells will not have LOH. Therefore, looking for tumour-related LOH has a disadvantage: requiring a difference that is higher than the threshold of the test based on signal-to-noise ratio. For example, when LOH is present in 1% of tumour cells, the proportion of missing alleles is 0.5%. To demonstrate this, a test is required that is able to make a distinction between 100% (normal reference DNA; e.g. lymphocytes) and 99.5% (mixed sample with 99% normal and 1% heterozygous tumour DNA). It is difficult to perceive a clinical assay with such a low variation coefficient that this small difference can be reliably detected in sputum.

Using polymorphic DNA markers in PCR-based assays, LOH and MSI has been reported in sputum of lung cancer patients. These polymorphic DNA markers are non-informative in individuals who are homozygotic for these markers. Therefore, several markers need to be examined to cover the general population.

Four studies have been conducted on LOH and lung cancer, of which the most recent ones were published in 2007 ([@bib2]; [@bib72]; [@bib9]; [@bib23]). No studies have followed since. All studies report comparable results with LOH in 26--55% in cases and 0--11% in cancer-free controls. Prevalence of MSI was low in all studies, ranging from 4 to 35% in cases and 0 to 5% in controls. [@bib2] tested 48 markers in sputum and bronchial washings (analysed together), in which non-cancer-specific markers were also included. Looking at informative loci, they calculated fractional allele loss values. Significant variations were observed for the markers, which may be related to non-neoplastic genetic alterations. This kind of results needs to be confirmed by others. Taking these data and the technical considerations into account, there is room for debate whether LOH and MSI by themselves are suitable as sputum biomarkers for lung cancer.

MicroRNA
--------

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules, which are associated with a spectrum of biological and pathological processes.

In a small feasibility study, [@bib73] demonstrated that endogenous miRNAs are stably present in sputum specimens. Using real-time RT--PCR, miR-21 and miR-155 were detected, of which miR-21 was significantly overexpressed in sputum of lung cancer patients as compared with cancer-free subjects. Furthermore, elevated miR-21 expression was more sensitive (70%) than conventional sputum cytology (48%) in diagnosing lung cancer.

The same research group defined miRNA signatures for different histologic types of lung cancer in studies of similar design ([@bib74]; [@bib75]). Sensitivity increased when complementary miRNAs were combined in a panel as compared with single miRNAs. For the diagnosis of squamous cell lung cancer, the combination of miR-205, miR-210 and miR-708 yielded 73% sensitivity and 96% specificity. A panel consisting of miR-21, miR-200b, miR-375 and miR-486 produced 81% sensitivity and 92% specificity in discriminating sputum of lung adenocarcinoma patients from controls. The authors found no association between miRNA expression and stage of lung cancer, suggesting that the miRNA signatures can be used as a tool in the detection of early lung cancer. Overall, miRNA analysis has recently become available and more studies in sputum seem useful.

Messenger RNA
-------------

From practical point of view, there is a disadvantage using messenger RNA (mRNA). In contrast to miRNA (see above), mRNA is rapidly degraded in the sputum. Therefore, it is necessary to process sputum after collection as soon as possible.

Several studies investigated aberrant mRNA profiles in sputum ([@bib26]; [@bib42]; [@bib65]) ([Table 2](#tbl2){ref-type="table"}). Reverse-transcriptase quantitative PCR (RTQ--PCR) was more sensitive than sputum cytology (14%) and immunocytochemistry (16%). In short, two studies revealed high specificity and reasonable sensitivity ([@bib26]; [@bib65]). Confirmation of these results is needed.

Protein
-------

Several studies explored the presence and/or expression of tumour-related proteins in sputum of lung cancer patients and controls ([Table 2](#tbl2){ref-type="table"}). [@bib65] reported significantly elevated expression of a proliferation-inducing ligand (APRIL) in sputum of lung cancer patients compared with controls (82% *vs* 3%, respectively).

[@bib49] demonstrated increased levels of complement factor H in sputum of lung cancer patients, and suggested that large plasma proteins as factor H reflects hyperpermeability in tumour circulation. Factor H quantification may aid in improving sensitivity of sputum cytology for lung cancer diagnosis, but is not proof of malignancy similar to hemoptysis.

Fluorescence *in situ* hybridisation
------------------------------------

Fluorescence *in situ* hybridisation (FISH) assay allows detection of chromosomal aneusomy, rearrangements and copy number changes in interphase cells, but usually requires the cytological or automated detection of abnormal cells. Fluorescence *in situ* hybridisation by itself is not superior to sputum cytology, but can improve sensitivity of lung cancer detection when used in conjunction with sputum cytology or as confirmatory test ([@bib54]; [@bib28]). [@bib38] showed that FISH analysis of both HYAL2 and FHIT deletions was more sensitive than cytology alone (sensitivity: 76% specificity: 92%). [@bib33] did not find significant differences in copy number gain between high-risk subjects and healthy never-smokers, indicating that copy number gain is not useful as a risk marker. [@bib50] used enrichment procedure based on anti-CD14 and anti-CD16 antibody beads before FISH and cytology. However, sensitivity of FISH and cytology results remained comparable (58% *vs* 53%). No internationally standardised method exists for cytometry ([@bib69]). So far, the data are useful for analysis on group level, but its relevance is questionable for the individual patient.

Other markers
-------------

Free DNA exists in higher concentration in the serum of lung cancer patients than in the serum of controls ([@bib64]). [@bib71] found that the amount of free DNA in sputum was related to severity of inflammation, but not in the presence of lung cancer.

In a small study, sequence variants in mitochondrial DNA (mtDNA) were investigated in specimens (no sputum) of lung, bladder and kidney cancer patients, and sputum from 12 cancer-free heavy smokers ([@bib25]). Tumours were found to contain significantly more mtDNA mutations compared with matched body fluids and blood, and sputum of controls. Biological relevance of mitochondrial mutations yet needs to be clarified.

Fourier transform infrared (FTIR) spectroscopy is a non-invasive method that visualises biochemical changes in sputum by determination of absorbance levels of infrared wavenumbers. In a small feasibility study, [@bib37] reported that a panel of wavenumbers was able to distinguish cancer sputum from healthy control sputum. Fourier transform infrared might have the potential as a high-throughput method for screening.

Black matter deposition (anthracosis) was assessed in sputum by [@bib34], next to DNA hypermethylation ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Mean anthracotic index of lung cancer patients was significantly higher than that in controls and might thus be suitable for identifying a population at risk for lung cancer development. Remarkably, this index was not correlated with smoking or with detection of lung cancer cells in the sputum samples.

Conclusion
==========

Ten years of additional research on the use of sputum in risk assessment or the early detection of lung cancer has brought new insights and more advanced molecular techniques. Polymerase chain reaction-based assays made detection of low fraction mutations feasible in sputum, although one has to be cautious for false-positivity induced by high number of PCR cycles. More biomarkers have been identified in sputum, such as DNA hypermethylation markers, miRNAs and tumour-related proteins, which show the potential for screening purposes. A rational for the distinction of a risk from a diagnostic marker was provided.

Although in recent years many markers have been examined in sputum, they are currently not sufficiently validated for clinical application. These studies, comparing sensitivity and specificity of cytology with molecular analysis, respecting technical limitations, should be reported in future studies.
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###### 
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###### Studies on *KRAS* and *p53* mutation analysis in sputum samples

             **Subjects**                                                                                                                   **Molecular alterations**                                                   
  ---------- ---------------- --------------- -------- ------------------------------------------------------------------------------------ --------------------------- --------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@bib3]                     Smokers         *KRAS*   PCR--RFLP                                                                            40                                                            0/506 (0%)    Follow-up 2--6 years; 18 patients developed lung cancer without molecular alterations at baseline
                                              *p53*    PCR and SSCP                                                                         40                                                            15/803 (2%)   One patient with *p53* mutation at baseline developed SqCC, but was not confirmed in resected tumour tissue. Also DNA promoter hypermethylation tested of *p16*, *NORE1A* and *RASSF1A* ([Supplementary Table 1](#sup1){ref-type="supplementary-material"})
  [@bib12]   NSCLC            Smokers         *KRAS*   PCR--RFLP                                                                            40                          11/50 (22%)                       0/100 (0%)    Fourteen of 50 tumour tissue samples tested *KRAS* mutation positive. In three cases, concomitant *p16* hypermethylation ([Supplementary Table 1](#sup1){ref-type="supplementary-material"})
  [@bib30]   All                              *KRAS*   MAE, PCR and DGGE                                                                    47                          XW: 23/102 (23%) BH: 7/50 (14%)                 Data of both tumour and sputum were presented together. Two study populations: Xuan Wei County (XW) and Beijing and Henan (BH), respectively. XW subjects were exposed to coal smoke
  [@bib29]   Lung cancer NS                   *KRAS*   Cell centrifugation, laser capture microdissection, PCR and DGGE (KRAS)/SSCP (p53)   47                          2/15 (13%)                                      Subjects were exposed to coal smoke. *KRAS* mutation status of primary tumour unknown
                                              *p53*                                                                                         42                          6/15 (40%)                                       
  [@bib31]                    (Non) Smokers   *KRAS*   Cell centrifugation, laser capture microdissection, PCR and DGGE (KRAS)/SSCP (p53)   30                                                            2/92 (2%)     Subjects were exposed to coal smoke
                                              *p53*                                                                                         42                                                            14/92 (15%)    
  [@bib76]   NSCLC                            *KRAS*   MAE, PCR and DGGE                                                                    55                          10/22 (46%)                                     In 12 out of 22 matched tumour--sputum samples, *KRAS* mutation was identified using the same method (*κ*=0.64, 95% confidence interval: 0.32--0.95, *P*\<0.01). One patient tested negative in tumour, but positive in sputum

Abbreviations: All=all types of lung cancer included; DGGE=denaturing gradient gel electrophoresis; MAE=mutant allele enrichment; NS=not specified; NSCLC=non-small-cell lung cancer; PCR=polymerase chain reaction; RFLP=restriction fragment length polymorphism; SqCC=squamous cell carcinoma; SSCP=single-strand conformational polymorphism.

###### Studies investigating presence and/or expression of RNA and tumour-related proteins in sputum

  **Study**                             **Cases**   **Controls**               **Method**                      **Protein/gene**                                 **Results cases**   **Results controls**   **Se (%)**   **Sp (%)**   **Positive cytology**                                 **Remarks**
  ------------------------------------- ----------- -------------------------- ------------------------------- ------------------------------------------------ ------------------- ---------------------- ------------ ------------ ----------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@bib65]                              All         Benign pulmonary disease   RTQ--PCR, immunocytochemistry   APRIL[a](#t2-fn2){ref-type="fn"}                 58/71 (82%)         2/62 (3%)              82           97           Cases 10/71 (14%): all SCC Immunocytol: 11/71 (16%)   Healthy subjects: 1/65 (2%). Cutoff value: mean±2 s.d. of mRNA expression in healthy subjects
  [@bib42][b](#t2-fn3){ref-type="fn"}   All         Benign pulmonary disease   RT--PCR                         MAGE-1                                           2/14 (14%)          0/2 (0%)               14           100          cases 1/8 (13%)                                       Positive cytology sample was not tested with RT--PCR. Cytology of remaining samples not performed
                                                                                                               MAGE-2                                           1/14 (7%)           0/2 (0%)               7            100                                                                 
                                                                                                               MAGE-3/6                                         0/14 (0%)           0/2 (0%)               0            100                                                                 
                                                                                                               MAGE-4                                           2/14 (14%)          0/2 (0%)               14           100                                                                 
                                                                                                               MAGE-12                                          2/14 (14%)          0/2 (0%)               14           100                                                                 
                                                                                                               All combined                                     5/14 (36%)          0/2 (0%)               36           100                                                                 
  [@bib26][b](#t2-fn3){ref-type="fn"}   All         Benign pulmonary disease   RT--N-PCR                       MAGE A1--6                                       72/134 (54%)        3/140 (2%)             54           98           Cases 6/31 (19%)                                      Also spontaneous sputum collected. Data of lung cancer patients from group I (collection at the day of thoracotomy) and II (lung cancer in clinical workup) combined. Follow-up (1 year): no cancer in controls
                                                                               TRAP method                     Telomerase                                       8/27 (30%)                                 30                                                                               
  [@bib47][b](#t2-fn3){ref-type="fn"}   All         Cancer-free subjects       TRAP method                     Telomerase                                       23/34 (68%)         3/30 (10%)             68           90                                                                  
  [@bib49][b](#t2-fn3){ref-type="fn"}   All         Cancer-free subjects       Anti-factor H antibodies        Complement factor H[a](#t2-fn2){ref-type="fn"}                                              80           88                                                                 Also spontaneous sputum collected. Se and Sp based on cutoff ROC curve
  [@bib27]                              All         Benign pulmonary disease   IRMA                            CEA[a](#t2-fn2){ref-type="fn"}                                                              57           95                                                                 Se and Sp based on cutoff ROC curves
                                                                               IRMA                            NSE[a](#t2-fn2){ref-type="fn"}                                                              19           95                                                                  
                                                                               IRMA                            CYFRA 21-1[a](#t2-fn2){ref-type="fn"}                                                       36           95                                                                  
  [@bib21][b](#t2-fn3){ref-type="fn"}   All         COPD                       IRMA                            CEA                                                                                         NS           NS           cases 4/50 (8%)                                       CEA median concentration. Cases: 713 ng ml^−1^, controls 518 ng ml^−1^
                                                                               IRMA                            NSE                                                                                         NS           NS                                                                 NSE median concentration. Cases: 12 ng ml^−1^, controls 13.7 ng ml^−1^
                                                                               RIA                             CYFRA 21-1[a](#t2-fn2){ref-type="fn"}                                                       86           75                                                                  

Abbreviations: All=all types of lung cancer included; CEA=carcinoembryonic antigen; COPD=chronic obstructive pulmonary disease; IRMA=immunoradiometric assay; NSE=neuron-specific enolase; NS=not specified; RIA=radioimmunoassay; ROC=receiver operating characteristic; RT--(Q)(N)--PCR=reverse transcriptase (quantitative) (nested)--polymerase chain reaction; Se=sensitivity; Sp=specificity; TRAP=telomeric repeat amplification protocol.

*P*\<0.05 significance level between cases and controls.

Induced sputum.

###### Box 1. Diagnostic *vs* risk marker

In context of evaluating the performance of a certain biomarker, we used the following approach for distinction between risk and diagnostic markers. As some asymptomatic lung cancer cases exist in a control population, an estimate for the expected number of undiagnosed lung cancer cases in the general/control population was made based on the following assumptions. A diagnostic biomarker test is able to detect lung cancer (arbitrary) 2 years before becoming symptomatic. Examining a high-risk population (e.g. heavy smokers), with a relative risk on lung cancer of approximately 12, 2.4% of the cases in the control population will be positive (2 (years) × 0.1% (approximate incidence ([@bib61])) × 12 (relative risk)). To be on the safe side with this simplified approach, in this review the threshold was set at 4%. Thus, if \>4% of the control patients had a positive test, this biomarker was regarded as risk marker.
